Wai Chun Bio-Technology Limited Logo

Wai Chun Bio-Technology Limited

0660.HK

(2.0)
Stock Price

0,07 HKD

-6.67% ROA

47.06% ROE

-0.72x PER

Market Cap.

12.689.224,00 HKD

-350.5% DER

0% Yield

-2.71% NPM

Wai Chun Bio-Technology Limited Stock Analysis

Wai Chun Bio-Technology Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Wai Chun Bio-Technology Limited Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (42.58%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

The stock's low PBV ratio (-0.76x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-384%), which means it has a small amount of debt compared to the ownership it holds

4 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

5 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (298), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

6 ROA

The stock's ROA (-6.42%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

9 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

10 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

11 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

Wai Chun Bio-Technology Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Wai Chun Bio-Technology Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Wai Chun Bio-Technology Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Wai Chun Bio-Technology Limited Revenue
Year Revenue Growth
2004 259.472.000
2005 297.638.000 12.82%
2006 132.418.000 -124.77%
2007 68.080.000 -94.5%
2008 82.480.000 17.46%
2009 13.137.000 -527.85%
2010 284.128.000 95.38%
2011 362.310.000 21.58%
2012 386.678.000 6.3%
2013 373.582.000 -3.51%
2014 394.116.000 5.21%
2015 376.808.000 -4.59%
2016 464.807.000 18.93%
2017 512.133.000 9.24%
2018 480.852.000 -6.51%
2019 579.231.000 16.98%
2019 579.231.000 0%
2020 567.553.000 -2.06%
2021 671.460.690 15.47%
2022 773.654.000 13.21%
2023 761.320.000 -1.62%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Wai Chun Bio-Technology Limited Research and Development Expenses
Year Research and Development Expenses Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Wai Chun Bio-Technology Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2004 30.708.000
2005 27.284.000 -12.55%
2006 24.467.000 -11.51%
2007 37.317.000 34.43%
2008 37.007.000 -0.84%
2009 24.964.000 -48.24%
2010 28.039.000 10.97%
2011 23.322.000 -20.23%
2012 30.999.000 24.77%
2013 29.136.000 -6.39%
2014 20.497.000 -42.15%
2015 16.902.000 -21.27%
2016 43.502.000 61.15%
2017 19.009.000 -128.85%
2018 22.716.000 16.32%
2019 21.370.000 -6.3%
2019 21.370.000 0%
2020 25.519.000 16.26%
2021 26.210.680 2.64%
2022 21.082.000 -24.33%
2023 18.824.000 -12%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Wai Chun Bio-Technology Limited EBITDA
Year EBITDA Growth
2004 -36.070.000
2005 -61.317.000 41.17%
2006 -55.522.000 -10.44%
2007 -64.957.000 14.52%
2008 -62.370.000 -4.15%
2009 -25.640.000 -143.25%
2010 29.612.000 186.59%
2011 30.809.000 3.89%
2012 -10.954.000 381.26%
2013 -19.692.000 44.37%
2014 -12.647.000 -55.7%
2015 -14.210.000 11%
2016 -32.359.000 56.09%
2017 -7.090.000 -356.4%
2018 -47.622.000 85.11%
2019 8.258.000 676.68%
2019 22.612.000 63.48%
2020 17.521.000 -29.06%
2021 31.606.160 44.56%
2022 14.893.000 -112.22%
2023 46.032.000 67.65%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Wai Chun Bio-Technology Limited Gross Profit
Year Gross Profit Growth
2004 6.819.000
2005 2.572.000 -165.12%
2006 -18.053.000 114.25%
2007 -21.764.000 17.05%
2008 -6.215.000 -250.19%
2009 309.000 2111.33%
2010 33.768.000 99.08%
2011 51.487.000 34.41%
2012 22.699.000 -126.82%
2013 8.798.000 -158%
2014 5.051.000 -74.18%
2015 1.823.000 -177.07%
2016 12.156.000 85%
2017 12.930.000 5.99%
2018 15.522.000 16.7%
2019 49.027.000 68.34%
2019 49.027.000 0%
2020 48.930.000 -0.2%
2021 60.123.634 18.62%
2022 50.413.000 -19.26%
2023 67.180.000 24.96%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Wai Chun Bio-Technology Limited Net Profit
Year Net Profit Growth
2004 -29.016.000
2005 -52.386.000 44.61%
2006 -53.913.000 2.83%
2007 -94.733.000 43.09%
2008 -66.110.000 -43.3%
2009 -22.743.000 -190.68%
2010 20.305.000 212.01%
2011 -3.729.000 644.52%
2012 -34.135.000 89.08%
2013 -22.170.000 -53.97%
2014 -17.704.000 -25.23%
2015 -19.596.000 9.66%
2016 -39.169.000 49.97%
2017 -17.399.000 -125.12%
2018 -53.617.000 67.55%
2019 8.988.000 696.54%
2019 8.988.000 0%
2020 995.000 -803.32%
2021 -14.363.405 106.93%
2022 -15.433.000 6.93%
2023 -26.936.000 42.7%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Wai Chun Bio-Technology Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2004 0
2005 0 0%
2006 -1 0%
2007 -1 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Wai Chun Bio-Technology Limited Free Cashflow
Year Free Cashflow Growth
2004 -27.614.000
2005 -4.480.000 -516.38%
2006 -27.418.000 83.66%
2007 -20.385.000 -34.5%
2008 -54.979.000 62.92%
2009 -27.174.000 -102.32%
2010 -38.904.000 30.15%
2011 -52.151.000 25.4%
2012 -116.537.000 55.25%
2013 128.312.000 190.82%
2014 -22.853.000 661.47%
2015 -9.591.000 -138.28%
2016 -21.015.000 54.36%
2017 654.000 3313.3%
2018 -13.452.000 104.86%
2019 1.319.000 1119.86%
2019 329.750 -300%
2020 -12.962.000 102.54%
2021 -16.398.000 20.95%
2022 17.235.000 195.14%
2023 423.000 -3974.47%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Wai Chun Bio-Technology Limited Operating Cashflow
Year Operating Cashflow Growth
2004 -18.505.000
2005 8.359.000 321.38%
2006 -23.652.000 135.34%
2007 -12.712.000 -86.06%
2008 -52.510.000 75.79%
2009 -26.610.000 -97.33%
2010 -34.667.000 23.24%
2011 -44.655.000 22.37%
2012 -112.953.000 60.47%
2013 132.411.000 185.3%
2014 -15.837.000 936.09%
2015 -6.849.000 -131.23%
2016 -14.734.000 53.52%
2017 8.928.000 265.03%
2018 -6.889.000 229.6%
2019 14.272.000 148.27%
2019 3.568.000 -300%
2020 -413.000 963.92%
2021 390.000 205.9%
2022 45.413.000 99.14%
2023 24.668.000 -84.1%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Wai Chun Bio-Technology Limited Capital Expenditure
Year Capital Expenditure Growth
2004 9.109.000
2005 12.839.000 29.05%
2006 3.766.000 -240.92%
2007 7.673.000 50.92%
2008 2.469.000 -210.77%
2009 564.000 -337.77%
2010 4.237.000 86.69%
2011 7.496.000 43.48%
2012 3.584.000 -109.15%
2013 4.099.000 12.56%
2014 7.016.000 41.58%
2015 2.742.000 -155.87%
2016 6.281.000 56.34%
2017 8.274.000 24.09%
2018 6.563.000 -26.07%
2019 12.953.000 49.33%
2019 3.238.250 -300%
2020 12.549.000 74.2%
2021 16.788.000 25.25%
2022 28.178.000 40.42%
2023 24.245.000 -16.22%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Wai Chun Bio-Technology Limited Equity
Year Equity Growth
2004 209.762.000
2005 149.356.000 -40.44%
2006 93.667.000 -59.45%
2007 4.416.000 -2021.08%
2008 -96.769.000 104.56%
2009 -87.078.000 -11.13%
2010 45.426.000 291.69%
2011 64.490.000 29.56%
2012 20.673.000 -211.95%
2013 31.914.000 35.22%
2014 7.945.000 -301.69%
2015 -19.014.000 141.79%
2016 -11.833.000 -60.69%
2017 -32.019.000 63.04%
2018 -45.283.000 29.29%
2019 -36.512.000 -24.02%
2020 -12.969.000 -181.53%
2021 6.037.000 314.83%
2022 10.539.000 42.72%
2023 12.039.000 12.46%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Wai Chun Bio-Technology Limited Assets
Year Assets Growth
2004 281.453.000
2005 221.933.000 -26.82%
2006 146.696.000 -51.29%
2007 70.227.000 -108.89%
2008 65.793.000 -6.74%
2009 40.425.000 -62.75%
2010 314.278.000 87.14%
2011 252.404.000 -24.51%
2012 380.920.000 33.74%
2013 210.124.000 -81.28%
2014 139.935.000 -50.16%
2015 148.902.000 6.02%
2016 148.048.000 -0.58%
2017 147.406.000 -0.44%
2018 146.735.000 -0.46%
2019 176.177.000 16.71%
2020 188.321.000 6.45%
2021 249.952.000 24.66%
2022 240.231.000 -4.05%
2023 265.548.999 9.53%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Wai Chun Bio-Technology Limited Liabilities
Year Liabilities Growth
2004 71.691.000
2005 72.577.000 1.22%
2006 53.029.000 -36.86%
2007 65.811.000 19.42%
2008 162.562.000 59.52%
2009 127.503.000 -27.5%
2010 268.852.000 52.58%
2011 187.914.000 -43.07%
2012 360.247.000 47.84%
2013 178.210.000 -102.15%
2014 131.990.000 -35.02%
2015 167.916.000 21.4%
2016 159.881.000 -5.03%
2017 179.425.000 10.89%
2018 192.018.000 6.56%
2019 212.689.000 9.72%
2020 201.290.000 -5.66%
2021 243.915.000 17.48%
2022 229.692.000 -6.19%
2023 253.510.000 9.4%

Wai Chun Bio-Technology Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3.81
Net Income per Share
-0.1
Price to Earning Ratio
-0.72x
Price To Sales Ratio
0.02x
POCF Ratio
0.18
PFCF Ratio
1.56
Price to Book Ratio
-0.33
EV to Sales
0.22
EV Over EBITDA
4.58
EV to Operating CashFlow
2.05
EV to FreeCashFlow
17.75
Earnings Yield
-1.4
FreeCashFlow Yield
0.64
Market Cap
0,01 Bil.
Enterprise Value
0,14 Bil.
Graham Number
0.73
Graham NetNet
-0.84

Income Statement Metrics

Net Income per Share
-0.1
Income Quality
-3.98
ROE
0.47
Return On Assets
-0.07
Return On Capital Employed
0.18
Net Income per EBT
2.86
EBT Per Ebit
-0.4
Ebit per Revenue
0.02
Effective Tax Rate
-0.75

Margins

Sales, General, & Administrative to Revenue
0.02
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.07
Operating Profit Margin
0.02
Pretax Profit Margin
-0.01
Net Profit Margin
-0.03

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.41
Free CashFlow per Share
0.05
Capex to Operating CashFlow
0.88
Capex to Revenue
0.1
Capex to Depreciation
3.61
Return on Invested Capital
0.27
Return on Tangible Assets
-0.07
Days Sales Outstanding
24.26
Days Payables Outstanding
47.93
Days of Inventory on Hand
17.25
Receivables Turnover
15.05
Payables Turnover
7.61
Inventory Turnover
21.15
Capex per Share
0.36

Balance Sheet

Cash per Share
0,36
Book Value per Share
0,07
Tangible Book Value per Share
0.07
Shareholders Equity per Share
-0.23
Interest Debt per Share
0.9
Debt to Equity
-3.51
Debt to Assets
0.51
Net Debt to EBITDA
4.18
Current Ratio
0.75
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
-0,12 Bil.
Invested Capital
86060998
Working Capital
-0,05 Bil.
Intangibles to Total Assets
0
Average Receivables
0,04 Bil.
Average Payables
0,08 Bil.
Average Inventory
28606000
Debt to Market Cap
10.75

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Wai Chun Bio-Technology Limited Dividends
Year Dividends Growth

Wai Chun Bio-Technology Limited Profile

About Wai Chun Bio-Technology Limited

Wai Chun Bio-Technology Limited, an investment holding company, manufactures and sells modified starch and other biochemical products in the People's Republic of China. It also trades in electronic parts and components, and electrical appliances; and athletic and athletic-style footwear, as well as working, safety, golf, and other functional shoes. The company was formerly known as Wai Chun Mining Industry Group Company Limited and changed its name to Wai Chun Bio-Technology Limited in September 2019. The company is headquartered in Admiralty, Hong Kong.

CEO
Mr. Ka Chun Lam
Employee
130
Address
Admiralty Centre 2
Admiralty,

Wai Chun Bio-Technology Limited Executives & BODs

Wai Chun Bio-Technology Limited Executives & BODs
# Name Age
1 Mr. David Fenn
Company Secretary
70
2 Mr. Ka Chun Lam
MD, Chief Executive Officer & Executive Chairman
70
3 Mr. Shen Chuan Feng
Founder
70

Wai Chun Bio-Technology Limited Competitors